Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High

PURPOSE: Microsatellite instability-high (MSI-H) colorectal carcinomas (CRCs) show high rates of response to immune checkpoint inhibitors (IOs). B2M mutations and protein loss have been proposed as causes of resistance to IOs, yet they are enriched in MSI-H CRC. We aimed to characterize B2M-mutant,...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JCO Precis Oncol
Hlavní autoři: Middha, Sumit, Yaeger, Rona, Shia, Jinru, Stadler, Zsofia K., King, Sarah, Guercio, Shanna, Paroder, Victoriya, Bates, David D.B., Rana, Satshil, Diaz, Luis A., Saltz, Leonard, Segal, Neil, Ladanyi, Marc, Zehir, Ahmet, Hechtman, Jaclyn F.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2019
Témata:
Original Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6469719/
https://ncbi.nlm.nih.gov/pubmed/31008436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.18.00321
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky